Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Replication of the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Diabetes Trial in Healthcare Claims

NCT04215523 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT04215523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04215523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Replication of the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Diabetes Trial in Healthcare Claims
Lead sponsor
Brigham and Women's Hospital
Phase
Observational
Overall status
Completed
Start date
July 8, 2019
Completion date
February 18, 2021
Enrollment
49,790 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes